Mantle Cell Lymphoma (MCL) Recruiting Phase 2 Trials for Ibrutinib (DB09053)

Also known as: Mantle Cell Lymphomas / Lymphoma, Mantle-Cell / Mantle-Cell Lymphoma / Lymphoma, Mantle Cell / Mantle Cell Lymphoma / B cell lymphoma / Centrocytic lymphoma / Mantle cell lymphoma NOS

IndicationStatusPhase
DBCOND0071979 (Mantle Cell Lymphoma (MCL))Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03478514Phase II Palbociclib +Ibrutinib in Mantle Cell LymphomaTreatment
NCT03710772Ibrutinib, Rituximab, Venetoclax, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Mantle Cell LymphomaTreatment
NCT02471391ABT-199 & Ibrutinib in Mantle Cell Lymphoma (AIM)Treatment
NCT01880567Ibrutinib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Older Patients With Newly Diagnosed Mantle Cell LymphomaTreatment